Fingerprint
Dive into the research topics of 'Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically